AbbVie Tries to Develop Hep C Regimen Without Interferon
Share
Follow Us
The Editors at Hepatitis Central
December 4, 2013
Find out about AbbVie Inc. and its progress in developing an oral treatment for Hepatitis C.
AbbVie Cites Positives In Hepatitis C Treatment
November 21, 2013
Michael Novinson
AbbVie Inc. said its oral treatment for hepatitis C showed about 96 percent of patients had no detectable levels of the virus after 12 weeks.
The late-stage trial was designed to evaluate a regimen that fuses two experimental drugs developed by AbbVie with an antiviral drug that has been used a hepatitis C treatment for decades. The 631 patients enrolled in the trial were diagnosed with the genotype 1 variant of the infection, which accounts for some 70 percent of hepatitis C cases.
Continue reading this entire article:
http://www.wbjournal.com/article/20131121/NEWS01/131129991/1002
